|Videos|February 7, 2022
SABCS 2021 Updates in CDK4/6 Inhibitors in Breast Cancer
Sara A. Hurvitz, MD; Aditya Bardia, MD, MPH; Patrick Neven, MD, PhD; and Kevin Kalinsky MD, MS, discuss SABCS 2021 updates on the use of CDK4/6 inhibitors in HR+/HER2 breast cancer.
Advertisement
Data from the following clinical trials are discussed:
- P1-18-16: First-line aromatase inhibitor + palbociclib with randomized switch to fulvestrant [Faslodex] + palbociclib upon detection of circulating ESR1 mutation in HR+/HER2 metastatic breast cancer patients: Global safety results of PADA-1, a UCBG-GINECO phase 3 trial
- PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2 advanced breast cancer across the MONALEESA studies
- PD13-03: Ribociclib [Kisqali], everolimus, exemestane [Aromasin] triplet therapy in HR+/HER2 advanced breast cancer after progression on a CDK4/6 inhibitor: Final efficacy, safety, and biomarker results from TRINITI-1
- PD02-04: Molecular plasticity of luminal A breast cancer and response to CDK4/6 inhibition: The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib
Advertisement
Related to this article
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
The CHMP has recommended the approval of sacituzumab govitecan/pembrolizumab for treatment-naive, PD-L1-positive metastatic TNBC in the European Union.
Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA has approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Advertisement
Advertisement
Trending on OncLive
1
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
2
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
3
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
4
Dr Tarantino on the Evolution of TROP2-Directed ADCs in First-Line TNBC
5